Atria Investments Inc Cuts Stock Holdings in Sanofi (NASDAQ:SNY)

Atria Investments Inc decreased its holdings in shares of Sanofi (NASDAQ:SNY) by 1.2% in the 4th quarter, Holdings Channel reports. The firm owned 106,033 shares of the company’s stock after selling 1,263 shares during the period. Atria Investments Inc’s holdings in Sanofi were worth $5,114,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Assetmark Inc. boosted its stake in Sanofi by 64.2% in the fourth quarter. Assetmark Inc. now owns 179,583 shares of the company’s stock worth $8,661,000 after buying an additional 70,208 shares in the last quarter. Glass Wealth Management Co LLC boosted its stake in Sanofi by 1.0% in the fourth quarter. Glass Wealth Management Co LLC now owns 31,145 shares of the company’s stock worth $1,502,000 after buying an additional 300 shares in the last quarter. Keybank National Association OH boosted its stake in Sanofi by 9.9% in the fourth quarter. Keybank National Association OH now owns 10,105 shares of the company’s stock worth $487,000 after buying an additional 913 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Sanofi by 8.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 151,945 shares of the company’s stock worth $7,328,000 after buying an additional 12,440 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC boosted its stake in Sanofi by 12.6% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 59,973 shares of the company’s stock worth $2,893,000 after buying an additional 6,701 shares in the last quarter. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the company. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Finally, StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $60.00.

Sanofi Stock Performance

NASDAQ:SNY opened at $59.42 on Friday. The firm has a market cap of $150.80 billion, a PE ratio of 23.86, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $59.72. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The business has a 50 day moving average price of $52.44 and a 200-day moving average price of $52.73.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Equities research analysts predict that Sanofi will post 4.36 earnings per share for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.